Skip to main content

Table 1 Characteristics stratified by AB0 blood groups and Rhesus factor expression in 518 EOC patients

From: AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer – a retrospective multi-centre study

  All patients (n = 518) AB0 blood group antigen p value* Rhesus factor p value*
A0 (n = 212, 40.9%) B0 (n = 76, 14.7%) AB (n = 33, 6.3%) 00 (n = 197, 38.1%) Pos (n = 431) Neg (n = 87)
FIGO tumor stage 0.4 1   0.7 1
 Ia 29 (5.6) 15 (51.7) 3 (10.3) 1 (3.4) 10 (34.5)   23 (79.3) 6 (20.7)  
 Ib 4 (0.8) 2 (50) 0 0 2 (50)   3 (75) 1 (25)  
 Ic 61 (11.8) 23 (37.7) 11 (18) 2 (3.3) 25 (41)   52 (86.7) 8 (13.3)  
 IIa 10 (1.9) 1 (10) 2 (20) 2 (20) 5 (50)   8 (80) 2 (20)  
 IIb 14 (2.7) 5 (35.7) 2 (14.3) 2 (14.3) 5 (35.7)   11 (78.6) 3 (21.4)  
 IIc 20 (3.9) 5 (25) 7 (35) 0 8 (40)   18 (90) 2 (10)  
 IIIa 17 (3.3) 6 (35.3) 3 (17.6) 0 8 (47.1)   14 (82.4) 3 (17.6)  
 IIIb 29 (5.6) 16 (55.2) 0 3 (10.3) 10 (34.5)   27 (93.1) 2 (6.9)  
 IIIc 262 (50.6) 107 (40.8) 40 (15.3) 15 (5.7) 100 (38.2)   218 (83.5) 43 (16.5)  
 IV 66 (12.7) 30 (45.5) 7 (10.6) 6 (9.1) 23 (34.8)   51 (77.3) 15 (22.7)  
 N/A 6 (1.2)         
Histologic Subtype 0.4 2   0.2 2
 High-grade serous 310 (59.8) 125 (40.3) 39 (12.6) 19 (6.1) 127 (41)   252 (81.6) 57 (18.4)  
 Low-grade serous 50 (9.7) 25 (50) 10 (20) 1 (2) 14 (28)   45 (90) 5 (10)  
 Mucinous 34 (6.6) 10 (29.4) 7 (20.6) 4 (11.8) 13 (38.2)   30 (90.9) 3 (9.1)  
 Endometrioid 72 (13.9) 30 (41.7) 9 (12.5) 6 (8.3) 27 (37.5)   59 (81.9) 13 (18.1)  
 Clear cell 12 (2.3) 7 (58.3) 2 (16.7) 0 3 (25)   10 (83.3) 2 (16.7)  
 Mixed epithelial 40 (7.7) 15 (37.5) 9 (22.5) 3 (7.5) 13 (32.5)   33 (82.5) 7 (17.5)  
Postoperative residual tumor 0.2 3   0.9 3
 none 229 (44.2) 83 (36.2) 36 (15.7) 9 (3.9) 101 (44.1)   190 (83.3) 38 (16.7)  
 ≤  1 cm 66 (12.7) 26 (39.4) 12 (18.2) 6 (9.1) 22 (33.3)   55 (83.3) 11 (16.7)  
 >  1 cm 117 (22.6) 47 (40.2) 16 (13.7) 10 (8.5) 44 (37.6)   93 (80.2) 23 (19.8)  
 N/A 106 (20.5)         
  1. *Pearson Chi-Square test; N/A not available; 1FIGO III and IV vs. FIGO I and II; 2high-grade serous and mixed epithelial vs. low-grade serous vs. mucinous vs. endometrial and clear cell adenocarcinoma; 3residual vs. no residual tumor